Navigation Links
Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
Date:9/15/2008

CAMBRIDGE, Mass., Sept. 15 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that it has met its second milestone in its option agreement with the Novartis Option Fund and will move on to the next phase to validate targets for inflammatory bowel disease (IBD) using Cequent's proprietary TransKingdom RNA interference [tkRNAi(TM)] technology in animal models. Specific payment terms and targets were not disclosed.

"IBD is actually a spectrum of diseases, and the power of RNAi is that you could potentially design therapeutics specifically to target the individual forms of the disease," said Cequent President and CEO, Peter Parker. "When we started the Novartis program, we were evaluating eight targets simultaneously as potential therapeutics for inflammatory bowel disease. Our milestone goal, which we accomplished, was to winnow the targets down to three that we will further validate in in vivo animal trials before Cequent selects the single target to be the subject of the Option agreement. We believe our success with this work, along with progress in our other development programs for Familial Polyposis (FAP) and Human Papilloma Virus (HPV), demonstrate the potential of our tkRNAi technology to become an important tool to better understand, and ultimately, to treat many devastating diseases."

Said Steven Tregay, PhD, a managing director of Novartis Option Fund, "We are impressed with both the quality and speed of the work that Cequent is doing on the IBD program -- as well as the potential of their tkRNAi platform. Creating compounds to address eight targets and completing in vitro screening in only nine months would have been virtually impossible with traditional small-molecule-based drug discovery technologies. We're pleased to release the milestone payment to Cequent, and look forward to our continued relationship both as venture
'/>"/>

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
2. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
3. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
4. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
5. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
6. VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16
7. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
8. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
9. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
10. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
11. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 25, 2014 Whitehouse Laboratories is ... the Morris County (New Jersey) Chamber of Commerce ... leading business organization in the North Jersey area, ... engage some key clients in the pharmaceutical and ... geographic area. Membership enables Whitehouse Laboratories a higher ...
(Date:11/26/2014)... 2014 Global biostimulants market is ... at an estimated CAGR of 12.5%. In order ... products with least ecological impacts, farmers are looking ... boost crop yield more effectively & efficiently. Biostimulants ... improve the return on investments. , Leading companies ...
(Date:11/26/2014)... , 25 novembre 2014 Theravalues Corporation ... sur le marché européen au salon Hi Europe ... Amsterdam ). Curcumine la plus ... technologie amorphe (non-cristalline) à des ingrédients approuvés par ... un pigment jaune présent dans la racine de ...
(Date:11/24/2014)... , UAE, November 24, 2014 ... Hamdan Bin Rashid Al Maktoum Awards for Medical Sciences", ... Dubai, United Arab Emirates , on 15 ... ) , The Carter Center which won ... is actively involved in numerous programs that aim to ...
Breaking Biology Technology:Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3Five US Winners Among Recipients of Hamdan Medical Awards 2
... Reportlinker.com announces that a new market ... Case Study: Personalized Cancer ... and companion diagnostic co-development ... The treatment of cancer ...
... Madison, Wis. If you,ve ever lost your keys or stuck ... you may have been the victim of a tired brain region ... of Wisconsin-Madison have a new explanation.,They,ve found that some nerve cells ... into a sleep-like state, while the rest of the brain appears ...
... have created a new kind of cloaking material ... range. Though this design can,t translate into ... could have implications in diagnostics, security, and communication. ... professor of mechanical engineering at Northwestern,s McCormick School ...
Cached Biology Technology:Reportlinker Adds Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development 2Reportlinker Adds Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development 3Brain regions can take short naps during wakefulness, leading to errors 2Researchers create terahertz invisibility cloak 2
(Date:11/4/2014)... SALT LAKE CITY, Nov. 5, 2014 – University of ... uses enzymes to help jet fuel produce electricity without ... can be used to power portable electronics, off-grid power ... appears online today in the American Chemical Society journal ... into electricity through a chemical reaction between a fuel ...
(Date:11/4/2014)... Temple University School of Medicine announced today that ... initiative funded by the Bill & Melinda Gates ... Obstetrics, Gynecology and Reproductive Sciences; and Vice Chair ... School of Medicine will pursue an innovative global ... Biomarkers to Assess Fetal Neurodevelopment.", Grand Challenges Explorations ...
(Date:11/4/2014)... examining only marketing directed at children on the ... found that the majority of black, middle-income and ... tactics. , Authored by Arizona State University researcher ... the first to examine the use of child-directed ... food restaurants and its relationship to demographics. It ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Temple University School of Medicine receives Grand Challenges Explorations grant 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3
... Following PETA,s call for U.S. Department of Agriculture,s (USDA) ... test the potency of each batch of a vaccine, the ... pigs have been replaced with modern non-animal methods. The USDA ... Specifically, PETA asked the CVB to follow the lead of ...
... b3c newswire / - ERGONEX Pharma received one of ... the occasion of Frost & Sullivan,s ,2009 Excellence in ... 2009. The highly competitive award was presented to ERGONEX ... its impressive display of technological know-how and targeted vision. ...
... 18, 2009 Fate Therapeutics, Inc. announced today the ... combination of small molecules that significantly improves the speed ... made by Sheng Ding, Ph.D. under a research collaboration ... represent a more than 200-fold improvement in reprogramming efficiency ...
Cached Biology News:ERGONEX Pharma receives Frost & Sullivan's European Orphan Diseases Entrepreneurial Company Award 2009 2Fate Therapeutics announces creation of small molecule platform for commercial-scale reprogramming 2
Clarin Mounting Medium (Permanent environmentally safe mounting medium for general histology & cytology use)...
IHC Zinc Fixative - , 1000 ml Consult technical datasheet for details....
Rabbit polyclonal to JNK1 (phospho T183 + Y185) ( Abpromise for all tested applications). entrezGeneID: 5599 SwissProtID: P45983...
Cytofix Buffer 100 mls...
Biology Products: